These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 24917414)

  • 1. Effects of flecainide on left ventricular pressure gradient and symptoms in obstructive hypertrophic cardiomyopathy: a comparison of flecainide and disopyramide.
    Haruki S; Minami Y; Suzuki A; Hagiwara N
    Heart Vessels; 2015 Sep; 30(5):604-10. PubMed ID: 24917414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy.
    Sherrid MV; Barac I; McKenna WJ; Elliott PM; Dickie S; Chojnowska L; Casey S; Maron BJ
    J Am Coll Cardiol; 2005 Apr; 45(8):1251-8. PubMed ID: 15837258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of disopyramide on left ventricular pressure gradient in hypertrophic obstructive cardiomyopathy in comparison with propranolol--a case report.
    Tokudome T; Mizushige K; Ueda T; Sakamoto S; Matsuo H
    Angiology; 1999 Apr; 50(4):331-5. PubMed ID: 10225470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral disopyramide for the acute treatment of severe outflow obstruction in hypertrophic cardiomyopathy in the ICU setting.
    Sirak TE; Sherrid MV
    Chest; 2008 May; 133(5):1243-6. PubMed ID: 18460523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Markers of responsiveness to disopyramide in patients with hypertrophic cardiomyopathy.
    Habib M; Hoss S; Bruchal-Garbicz B; Chan RH; Rakowski H; Williams L; Adler A
    Int J Cardiol; 2019 Dec; 297():75-82. PubMed ID: 31615649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiarrhythmic drug cibenzoline attenuates left ventricular pressure gradient and improves transmitral Doppler flow pattern in patients with hypertrophic obstructive cardiomyopathy caused by midventricular obstruction.
    Hamada M; Shigematsu Y; Inaba S; Aono J; Ikeda S; Watanabe K; Ogimoto A; Ohtsuka T; Hara Y; Higaki J
    Circ J; 2005 Aug; 69(8):940-5. PubMed ID: 16041163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A primer of disopyramide treatment of obstructive hypertrophic cardiomyopathy.
    Sherrid MV; Arabadjian M
    Prog Cardiovasc Dis; 2012; 54(6):483-92. PubMed ID: 22687589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An equation to predict the changes in peak left ventricular pressure in hypertrophic obstructive cardiomyopathy after treatment: application to the administration of disopyramide.
    Niki K; Sugawara M; Tanino S; Iwade K; Hosoda S; Kasanuki H
    Heart Vessels; 1999; 14(2):72-81. PubMed ID: 10651183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disopyramide use in infants and children with hypertrophic cardiomyopathy.
    O'Connor MJ; Miller K; Shaddy RE; Lin KY; Hanna BD; Ravishankar C; Rossano JW
    Cardiol Young; 2018 Apr; 28(4):530-535. PubMed ID: 29513203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disopyramide for Hypertrophic Cardiomyopathy: A Pragmatic Reappraisal of an Old Drug.
    Verlinden NJ; Coons JC
    Pharmacotherapy; 2015 Dec; 35(12):1164-72. PubMed ID: 26684556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paradoxical response to exercise in asymptomatic hypertrophic cardiomyopathy: a new description of outflow tract obstruction dynamics.
    Lafitte S; Reant P; Touche C; Pillois X; Dijos M; Arsac F; Peyrou J; Montaudon M; Ritter P; Roudaut R; Demaria A
    J Am Coll Cardiol; 2013 Aug; 62(9):842-50. PubMed ID: 23810875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Class Ia antiarrhythmic drug cibenzoline: a new approach to the medical treatment of hypertrophic obstructive cardiomyopathy.
    Hamada M; Shigematsu Y; Ikeda S; Hara Y; Okayama H; Kodama K; Ochi T; Hiwada K
    Circulation; 1997 Sep; 96(5):1520-4. PubMed ID: 9315541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salutary effect of disopyramide on left ventricular diastolic function in hypertrophic obstructive cardiomyopathy.
    Matsubara H; Nakatani S; Nagata S; Ishikura F; Katagiri Y; Ohe T; Miyatake K
    J Am Coll Cardiol; 1995 Sep; 26(3):768-75. PubMed ID: 7642872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy of continuous intravenous drip infusion of disopyramide in hypertrophic obstructive cardiomyopathy during cardiogenic shock: a case report].
    Kajimoto K; Harada T; Imamura K; Matsuda N; Niki K; Hagiwara N; Kasanuki H
    J Cardiol; 2000 Mar; 35(3):197-203. PubMed ID: 10808427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disopyramide is a safe and effective treatment for children with obstructive hypertrophic cardiomyopathy.
    Topriceanu CC; Field E; Boleti O; Cervi E; Kaski JP; Norrish G
    Int J Cardiol; 2023 Jan; 371():523-525. PubMed ID: 36174821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long term exercise capacity in patients with hypertrophic cardiomyopathy treated with percutaneous transluminal septal myocardial ablation.
    Malek LA; Chojnowska L; Klopotowski M; Maczynska R; Demkow M; Witkowski A; Kusmierczyk B; Piotrowicz E; Konka M; Dabrowski M; Ruzyllo W
    Eur J Heart Fail; 2008 Nov; 10(11):1123-6. PubMed ID: 18840395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of acute reduction in left ventricular outflow tract pressure gradient in obstructive hypertrophic cardiomyopathy by disopyramide versus pilsicainide versus cibenzoline.
    Kajimoto K; Imai T; Minami Y; Kasanuki H
    Am J Cardiol; 2010 Nov; 106(9):1307-12. PubMed ID: 21029829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of chronic use of cibenzoline on left ventricular pressure gradient and left ventricular remodeling in patients with hypertrophic obstructive cardiomyopathy.
    Hamada M; Ikeda S; Ohshima K; Nakamura M; Kubota N; Ogimoto A; Shigematsu Y
    J Cardiol; 2016 Mar; 67(3):279-86. PubMed ID: 26116980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mid-systolic drop in left ventricular ejection velocity in obstructive hypertrophic cardiomyopathy--the lobster claw abnormality.
    Sherrid MV; Gunsburg DZ; Pearle G
    J Am Soc Echocardiogr; 1997 Sep; 10(7):707-12. PubMed ID: 9339420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Negative ionotropic agents for the treatment of left ventricular outflow tract obstruction due to sigmoid septum and concentric left ventricular hypertrophy.
    Ranasinghe I; Yeoh T; Yiannikas J
    Heart Lung Circ; 2011 Sep; 20(9):579-86. PubMed ID: 21684204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.